News | December 11, 2025
Bristol Myers Squibb unveils breakthrough Lymphoma data
Golcadomide, a CELMoD agent, continued to deliver deep and durable responses in aggressive B-cell and follicular lymphomas
Golcadomide, a CELMoD agent, continued to deliver deep and durable responses in aggressive B-cell and follicular lymphomas
India has deep strengths in reverse engineering and API development, while Russia has strong capabilities in certain vaccines, biologicals, and niche therapeutic segments. Collaboration can significantly shorten R&D timelines
The new site will produce next-generation synthetic medicine active pharmaceutical ingredients
Dr Reddy’s will pay Immutep US$ 20 million upfront and could deliver as much as US$ 349.5 million in regulatory and commercial milestones
Acetaminophen Injection is indicated for the management of mild to moderate pain in adult and pediatric patients 2 years and older
The partnership also allows both companies to explore CR-001 and SKB105 as monotherapies and in combination
Biocon will acquire all of Viatris’ convertible preferred equity in Biocon Biologics for $400 million in cash and $415 million in newly issued Biocon shares
HYMPAVZI’s safety profile was generally favorable
Captured microbes are then neutralized on engineered microbicidal surfaces
MRI is particularly valuable in pediatric care due to its non-invasive nature
Subscribe To Our Newsletter & Stay Updated
